TY  - JOUR
AU  - Dugalić, Predrag
AU  - Đuranović, Srđan
AU  - Dugalić, Vladimir
AU  - Stanković, Marjan
AU  - Isenović, Esma
PY  - 2023
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12024
AB  - Introduction: Barrett’s esophagus (BE) represents the distal esophageal epithelium changes that carry a high risk of developing esophageal adenocarcinoma. One of the most challenging aspects of diagnosing BE by endoscopy is precisely discerning between normal epithelium and BE changes, which is essential for therapy success. The objectives of this study were to compare the success of radio-frequency ablation (RFA) therapy to conservative treatment with proton pump inhibitor (PPI) drugs between the clinical presentation and endoscopy findings of BE at 2, 6, 12, and 24 months after administered therapy. Material and methods: Seventy-five subjects were divided into two groups (RFA and PPI) based on the BE treatment regimen in this case-control study to compare the quality of treatments applied over a  24-month follow-up. Subjects who received RFA therapy were further divided into groups: those who received focal HALO 90 and those who received circumferential HALO 360, based primarily on EGDS findings or endoscopist experience. Results: The results show that using the RFA therapeutic modality in the treatment of BE is more effective (by 94.2% in the second month of follow-up, i.e., by 99% at the final visit after 24 months) than using PPI therapy alone. Re-RFA therapy was given to 15% of the subjects, mostly applied in the same therapeutic modality (HALO 90). Conclusions: Our findings show that RFA and re-RFA therapy have a  high efficacy and safety profile, with no registered worsening of histology findings, the occurrence of esophageal adenocarcinoma, or adverse effects of the therapy.
T2  - Archives of Medical Science
T1  - Treatment of Barrett's Esophagus with radiofrequency ablation
DO  - 10.5114/aoms/159314
ER  - 

@article{
author = "Dugalić, Predrag and Đuranović, Srđan and Dugalić, Vladimir and Stanković, Marjan and Isenović, Esma",
year = "2023",
abstract = "Introduction: Barrett’s esophagus (BE) represents the distal esophageal epithelium changes that carry a high risk of developing esophageal adenocarcinoma. One of the most challenging aspects of diagnosing BE by endoscopy is precisely discerning between normal epithelium and BE changes, which is essential for therapy success. The objectives of this study were to compare the success of radio-frequency ablation (RFA) therapy to conservative treatment with proton pump inhibitor (PPI) drugs between the clinical presentation and endoscopy findings of BE at 2, 6, 12, and 24 months after administered therapy. Material and methods: Seventy-five subjects were divided into two groups (RFA and PPI) based on the BE treatment regimen in this case-control study to compare the quality of treatments applied over a  24-month follow-up. Subjects who received RFA therapy were further divided into groups: those who received focal HALO 90 and those who received circumferential HALO 360, based primarily on EGDS findings or endoscopist experience. Results: The results show that using the RFA therapeutic modality in the treatment of BE is more effective (by 94.2% in the second month of follow-up, i.e., by 99% at the final visit after 24 months) than using PPI therapy alone. Re-RFA therapy was given to 15% of the subjects, mostly applied in the same therapeutic modality (HALO 90). Conclusions: Our findings show that RFA and re-RFA therapy have a  high efficacy and safety profile, with no registered worsening of histology findings, the occurrence of esophageal adenocarcinoma, or adverse effects of the therapy.",
journal = "Archives of Medical Science",
title = "Treatment of Barrett's Esophagus with radiofrequency ablation",
doi = "10.5114/aoms/159314"
}

Dugalić, P., Đuranović, S., Dugalić, V., Stanković, M.,& Isenović, E.. (2023). Treatment of Barrett's Esophagus with radiofrequency ablation. in Archives of Medical Science.
https://doi.org/10.5114/aoms/159314

Dugalić P, Đuranović S, Dugalić V, Stanković M, Isenović E. Treatment of Barrett's Esophagus with radiofrequency ablation. in Archives of Medical Science. 2023;.
doi:10.5114/aoms/159314 .

Dugalić, Predrag, Đuranović, Srđan, Dugalić, Vladimir, Stanković, Marjan, Isenović, Esma, "Treatment of Barrett's Esophagus with radiofrequency ablation" in Archives of Medical Science (2023),
https://doi.org/10.5114/aoms/159314 . .

TY  - JOUR
AU  - Dugalić, Predrag
AU  - Đuranović, Srđan
AU  - Pavlović-Marković, Aleksandra
AU  - Dugalić, Vladimir
AU  - Tomašević, Ratko
AU  - Gluvić, Zoran
AU  - Obradović, Milan M.
AU  - Bajić, Vladan P.
AU  - Isenović, Esma R.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9104
AB  - Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the dis-tal oesophagus, and this may cause the development of reflux esophagitis and Barrett’s oesophagus (BE). The natural histological course of untreated BE is non-dysplastic or benign BE (ND), then low-grade (LGD) and High-Grade Dysplastic (HGD) BE, with the expected increase in malignancy transfer to oesophagal adenocarcinoma (EAC). The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol. The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control. It is noteworthy that long-term use of PPIs increases gastrin level, which can contribute to transfer from BE to EAC, as a result of its effects on the proliferation of BE epithelium. Endoscopy treatment includes a wide range of re-section and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy). RFA promotes mucosal necrosis of treated oesophagal region via high-frequency energy. Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease. This review aims to explain distinct effects of PPIs and RFA modalities, illuminate certain aspects of molecular mechanisms involved, as well as the effects of their concomitant use regarding the treatment of BE and prevention of its transfer to EAC.
T2  - Mini-Reviews in Medicinal Chemistry
T1  - Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus
VL  - 20
IS  - 11
SP  - 975
EP  - 987
DO  - 10.2174/1389557519666191015203636
ER  - 

@article{
author = "Dugalić, Predrag and Đuranović, Srđan and Pavlović-Marković, Aleksandra and Dugalić, Vladimir and Tomašević, Ratko and Gluvić, Zoran and Obradović, Milan M. and Bajić, Vladan P. and Isenović, Esma R.",
year = "2020",
abstract = "Gastroesophageal Reflux Disease (GERD) is characterized by acid and bile reflux in the dis-tal oesophagus, and this may cause the development of reflux esophagitis and Barrett’s oesophagus (BE). The natural histological course of untreated BE is non-dysplastic or benign BE (ND), then low-grade (LGD) and High-Grade Dysplastic (HGD) BE, with the expected increase in malignancy transfer to oesophagal adenocarcinoma (EAC). The gold standard for BE diagnostics involves high-resolution white-light endoscopy, followed by uniform endoscopy findings description (Prague classification) with biopsy performance according to Seattle protocol. The medical treatment of GERD and BE includes the use of proton pump inhibitors (PPIs) regarding symptoms control. It is noteworthy that long-term use of PPIs increases gastrin level, which can contribute to transfer from BE to EAC, as a result of its effects on the proliferation of BE epithelium. Endoscopy treatment includes a wide range of re-section and ablative techniques, such as radio-frequency ablation (RFA), often concomitantly used in everyday endoscopy practice (multimodal therapy). RFA promotes mucosal necrosis of treated oesophagal region via high-frequency energy. Laparoscopic surgery, partial or total fundoplication, is reserved for PPIs and endoscopy indolent patients or in those with progressive disease. This review aims to explain distinct effects of PPIs and RFA modalities, illuminate certain aspects of molecular mechanisms involved, as well as the effects of their concomitant use regarding the treatment of BE and prevention of its transfer to EAC.",
journal = "Mini-Reviews in Medicinal Chemistry",
title = "Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus",
volume = "20",
number = "11",
pages = "975-987",
doi = "10.2174/1389557519666191015203636"
}

Dugalić, P., Đuranović, S., Pavlović-Marković, A., Dugalić, V., Tomašević, R., Gluvić, Z., Obradović, M. M., Bajić, V. P.,& Isenović, E. R.. (2020). Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. in Mini-Reviews in Medicinal Chemistry, 20(11), 975-987.
https://doi.org/10.2174/1389557519666191015203636

Dugalić P, Đuranović S, Pavlović-Marković A, Dugalić V, Tomašević R, Gluvić Z, Obradović MM, Bajić VP, Isenović ER. Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus. in Mini-Reviews in Medicinal Chemistry. 2020;20(11):975-987.
doi:10.2174/1389557519666191015203636 .

Dugalić, Predrag, Đuranović, Srđan, Pavlović-Marković, Aleksandra, Dugalić, Vladimir, Tomašević, Ratko, Gluvić, Zoran, Obradović, Milan M., Bajić, Vladan P., Isenović, Esma R., "Proton Pump Inhibitors and Radiofrequency Ablation for Treatment of Barrett's Esophagus" in Mini-Reviews in Medicinal Chemistry, 20, no. 11 (2020):975-987,
https://doi.org/10.2174/1389557519666191015203636 . .